Ocuphire Pharma Inc expected to post a loss of 24 cents a share - Earnings Preview

Opus Genetics

07/08/2024 16:22

* Ocuphire Pharma Inc  OCUP.OQ   OCUP.O  is expected to show
a
fall in quarterly revenue when it reports  results on August 9
(estimated) for the period ending June 30 2024
    * The Farmington Hills Michigan-based  company is expected
to
report a 28.9% decrease in revenue to $2.613 million from $3.67
million a year ago, according to the mean estimate from 3
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Ocuphire Pharma Inc is
for a
loss of 24 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Ocuphire
Pharma
Inc is $19.00​, above​ its last closing price of $1.72. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  -0.11       -0.13      -0.29     Missed  -116.4
 Dec. 31 2024  -0.03       -0.05      -0.21     Missed  -300
 Sep. 30 2023  -0.24       -0.22      0.25      Beat    212.6​
 Jun. 30 2023  -0.25       -0.23      -0.24     Missed  -6.2
 ​​Mar.        -0.18       -0.15      -0.28     Missed  -81.8
 31 2023                                                
 Dec. 31 2022              0.97       1.58      Beat    63.3​
 Sep. 30 2022  -0.29       -0.29      -0.22     Beat    23.7
 Jun. 30 2022  -0.33       -0.33      -0.25     Beat    24.7
 This summary was machine generated August 7 at 15:22 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)